Cancer Innovation最新文献

{"title":"Ground glass nodules with scattered or eccentric island-shaped consolidations may have poor outcomes","authors":"Ming Li,&nbsp;Junjie Xi,&nbsp;Huan Zhang,&nbsp;Xing Jin,&nbsp;Zhuoyang Fan,&nbsp;Cheng Zhan,&nbsp;Mingxiang Feng,&nbsp;Lijie Tan,&nbsp;Qun Wang","doi":"10.1002/cai2.48","DOIUrl":"https://doi.org/10.1002/cai2.48","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To explore the effect of scattered or eccentric shaped types of ground glass opacity (GGO) on outcomes of patients with solid-dominant peripheral lung adenocarcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We evaluated patients with solid-dominant peripheral lung adenocarcinoma, who underwent radical surgery at Zhongshan Hospital, Fudan University, between January 2013 and December 2015. Morphologically heterogeneous solid-dominant lung adenocarcinoma in imaging findings was based on the last preoperative computed tomography (CT) scans. Endpoints were recurrence-free survival (RFS) and overall survival (OS). Kaplan–Meier analysis and the log-rank test were used to estimate survival differences. Impact factors were assessed by univariable logistic regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We retrospectively collected data from 200 patients, including 170 patients with central island-shaped CT imaging, 18 patients with scattered shaped CT imaging, and 12 patients with eccentric shaped CT imaging. Eleven patients experienced recurrence or metastases. Kaplan–Meier survival curves showed significant survival differences between the central island-shaped type and scattered shaped or eccentric shaped type for OS (c-stage IA: 5-year OS: 100% vs. 92.1%; HR = 0.019, <i>p</i> = 0.0025; p-stage IA: 100% vs. 95.2%; HR = 0.146, <i>p</i> = 0.1139) and RFS (c-stage IA: 5-year RFS: 100% vs. 59.7%; HR = 0.001, <i>p</i> &lt; 0.0001; p-stage IA: 100% vs. 64.5%; HR &lt; 0.001, <i>p</i> &lt; 0.0001). Univariable logistic regression analysis showed that scattered and eccentric shaped types were related to poor outcomes (<i>p</i> &lt; 0.012, odds ratio = 18.8).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Relative spatial position of GGO and solid components may affect patient outcomes. Patients with scattered or eccentric shaped GGO may have a poor prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects","authors":"Sadik Ali Mohammad,&nbsp;Arshadul Hak,&nbsp;Sunil V. Pogu,&nbsp;Aravind K. Rengan","doi":"10.1002/cai2.53","DOIUrl":"https://doi.org/10.1002/cai2.53","url":null,"abstract":"<p>Local therapy modalities such as radiation therapy, photodynamic therapy, photothermal therapy, and cryoablation have been used to treat localized tumors for decades. The discovery of the abscopal effect causes a paradigm shift where local therapy also causes systemic effects and leads to the remission of nonirradiated tumors. The abscopal effect of radiation therapy, alone or in combination with other treatments, has been extensively studied over the last six decades. However, the results are unsatisfactory in producing robust, reproducible, and long-lasting systemic effects. Although immunotherapy and radiation therapy are promising in producing the abscopal effect, the abscopal effect's mechanism is still unclear, owing to various factors such as irradiation type and dose and cancer type. This article reviews the research progress, clinical and preclinical evidence of the abscopal effect by various local therapies alone and in combination with chemotherapy and immunotherapy, case reports, and the current challenges in producing the abscopal effect by various local therapies, focusing on radiotherapy, photodynamic therapy, cryoablation, and the prospects for obtaining a robust, reproducible, and long-lasting abscopal effect.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71976428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ecological view of carcinogenesis: Niche-altering (NC3) mechanisms","authors":"Mesut Tez","doi":"10.1002/cai2.54","DOIUrl":"https://doi.org/10.1002/cai2.54","url":null,"abstract":"<p>Over the last 30 years, a new actor in the area of ecology and evolution has emerged: niche construction theory (NCT). The fundamental premise of NCT is that organisms may actively influence evolutionary processes by modifying their circumstances [<span>1</span>]⁠.</p><p>According to Trappes et al., [<span>2</span>] the concept of niche construction should only be applied to species that alter their environment, which they believe to be its intuitive scope. They add two more terms to describe the ways that organisms engage with their surroundings and so influence their niches: when organisms choose their environment, this is known as niche choice, and when they adapt their phenotype to fit their environment, this is known as niche conformance. These three concepts are often referred to as niche-altering mechanisms, or NC³ mechanisms: niche conformance, niche construction, and niche choice. This is in line with definitions of mechanisms developed in scientific philosophy [<span>2</span>]⁠.</p><p>Cancer was attempted to be explained using NC³ mechanisms in this essay.</p><p>Carcinogenesis is a three-stage process that includes initiation, progression, and metastasis [<span>3</span>]. Cancer initiation is an example of niche conformance. Phenotypic plasticity, or an organism's ability to develop distinct phenotypes in response to environmental variation, is involved in niche conformance. Unlike phenotypic plasticity, niche conformance also includes how phenotypic adjustment leads to changes in the phenotype-environment match and fitness [<span>2</span>]⁠.</p><p>The constant replacement of old cells with newly formed healthy differentiated cells (progeny) originating from adult stem cells regulates epithelial tissue turnover. Each differentiated cell in an organism expresses a subset of all the genes found in that species' genome. The pattern of gene expression defines a differentiated cell type (hepatocyte, enterocyte, and so on). Adult stem cells are thought to reside in many tissues within a niche formed by a group of cells and an extracellular matrix that provides an optimal environment for the adult stem cell. Furthermore, adult stem cells are resistant to apoptosis, making them more resistant to the damaging effects of environmental stress than their progeny [<span>4, 5</span>]⁠⁠.</p><p>The stress stimulus exposure consists of all current environmental parameters (including the stress stimulus) as well as the organism's phenome (all features of the organism at that moment). The phenomenon of ‘this particular moment’ bears the effects of all previous encounters; the organism has plasticity (the phenomenal repertoire it can demonstrate in response to environmental changes) and abilities due to all previous processes (both from the organism's own life process and from the processes of its ancestors). The organism's plasticity in the face of a stress stimulus is related to its genome, epigenome, phenom, and environment, whi","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in medical treatment of breast cancer in 2022","authors":"Jingtong Zhai,&nbsp;Yun Wu,&nbsp;Fei Ma,&nbsp;Virginia Kaklamani,&nbsp;Binghe Xu","doi":"10.1002/cai2.46","DOIUrl":"https://doi.org/10.1002/cai2.46","url":null,"abstract":"<p>Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.46","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging roles of circular RNAs in the invasion and metastasis of head and neck cancer: Possible functions and mechanisms","authors":"Shouyi Tang,&nbsp;Luyao Cai,&nbsp;Zhen Wang,&nbsp;Dan Pan,&nbsp;Qing Wang,&nbsp;Yingqiang Shen,&nbsp;Yu Zhou,&nbsp;Qianming Chen","doi":"10.1002/cai2.50","DOIUrl":"10.1002/cai2.50","url":null,"abstract":"<p>Head and neck cancer (HNC) is the seventh most prevalent malignancy worldwide in 2020. Cancer metastasis is the main cause of poor prognosis in HNC patients. Recently, circular RNAs (circRNAs), initially thought to have no biological function, are attracting increasing attention, and their crucial roles in mediating HNC metastasis are being extensively investigated. Existing studies have shown that circRNAs primarily function through miRNA sponges, transcriptional regulation, interacting with RNA-binding proteins (RBPs) and as translation templates. Among these functions, the function of miRNA sponge is the most prominent. In this review, we summarized the reported circRNAs involved in HNC metastasis, aiming to elucidate the regulatory relationship between circRNAs and HNC metastasis. Furthermore, we summarized the latest advances in the epidemiological information of HNC metastasis and the tumor metastasis theories, the biogenesis, characterization and functional mechanisms of circRNAs, and their potential clinical applications. Although the research on circRNAs is still in its infancy, circRNAs are expected to serve as prognostic markers and effective therapeutic targets to inhibit HNC metastasis and significantly improve the prognosis of HNC patients.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90683775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoting the application of pediatric radiomics via an integrated medical engineering approach","authors":"Haige Zheng,&nbsp;Fang Wang,&nbsp;Yang Li,&nbsp;Zhicheng Li,&nbsp;Xiaochun Zhang,&nbsp;Xuntao Yin","doi":"10.1002/cai2.44","DOIUrl":"https://doi.org/10.1002/cai2.44","url":null,"abstract":"<p>Radiomics is widely used in adult tumors but has been rarely applied to the field of pediatrics. Promoting the application of radiomics in pediatric diseases, especially in the early diagnosis and stratified treatment of tumors, is of great value to the realization of the WHO 2030 “Global Initiative for Childhood Cancer.” This paper discusses the general characteristics of radiomics, the particularity of its application to pediatric diseases, and the current status and prospects of pediatric radiomics. Radiomics is a data-driven science, and the combination of medicine and engineering plays a decisive role in improving data quality, data diversity, and sample size. Compared with adult radiomics, pediatric radiomics is significantly different in data type, disease spectrum, disease staging, and progression. Some progress has been made in the identification, classification, stratification, survival prediction, and prognosis of tumor diseases. In the future, big data applications from multiple centers and cross-talent training should be strengthened to improve the benefits for clinical workers and children.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives","authors":"Ziyi Xu,&nbsp;Zihua Zou,&nbsp;Xuezhi Hao,&nbsp;Puyuan Xing,&nbsp;Junling Li","doi":"10.1002/cai2.49","DOIUrl":"https://doi.org/10.1002/cai2.49","url":null,"abstract":"<p>Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early-stage or locally advanced non-small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at 5 years. At present, peri-operative treatment methods are emerging to prevent early relapse, such as targeted therapy and immunotherapy. Investigation on predictive biomarkers of responses to adjuvant and neoadjuvant therapies is also continuously ongoing. Immunotherapy represented by immune checkpoint inhibitors (ICIs), either by monotherapy or in combination with chemotherapy, has shown benefit in promoting pathological responses and prolonging survival for patients with NSCLC without oncogenic mutations. Exploratory studies have also provided evidence regarding the selection of patients who benefit from ICI-based perioperative treatment. This review focuses on the existing data of current clinical trials of adjuvant and neoadjuvant strategies with ICIs in resectable NSCLC, the exploration of predictive biomarkers, and the perspectives and urgent challenges in the future.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symphony in the crowd: Key genetic alterations in prostate cancer","authors":"Neshat Masud","doi":"10.1002/cai2.52","DOIUrl":"https://doi.org/10.1002/cai2.52","url":null,"abstract":"<p>Androgen receptor (AR) signaling have been frequently targeted for treating prostate cancer (PCa). Even though primarily patients receive a good therapeutic outcome by targeting AR signaling axis, eventually it emerges resistance by altering the genetic makeup of prostate cells. However, to develop an effective therapeutic regime, it is essential to recognize key genetic alterations in PCa. The most common genetic alterations that give rise to distinct androgen different differentiation states are gene fusion of TMPRSS2 with ETS family genes, deletion, or mutation of tumor suppressor <i>PTEN</i> and <i>TP53</i> gene, amplification or splicing of AR, altered DNA repair genes. In this review, we describe key genes and genetic changes that have been recognized to contribute to altered prostate environment.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50125757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of death rates for cardiovascular diseases and cancers","authors":"Oleg Gaidai,&nbsp;Yihan Xing,&nbsp;Rajiv Balakrishna,&nbsp;Jiayao Sun,&nbsp;Xiaolong Bai","doi":"10.1002/cai2.47","DOIUrl":"https://doi.org/10.1002/cai2.47","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To estimate cardiovascular and cancer death rates by regions and time periods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>Novel statistical methods were used to analyze clinical surveillance data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A multicenter, population-based medical survey was performed. Annual recorded deaths from cardiovascular diseases were analyzed for all 195 countries of the world. It is challenging to model such data; few mathematical models can be applied because cardiovascular disease and cancer data are generally not normally distributed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A novel approach to assessing the biosystem reliability is introduced and has been found to be particularly suitable for analyzing multiregion environmental and healthcare systems. While traditional methods for analyzing temporal observations of multiregion processes do not deal with dimensionality efficiently, our methodology has been shown to be able to cope with this challenge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our novel methodology can be applied to public health and clinical survey data.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.47","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50135962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study","authors":"Ying Cheng,&nbsp;Qiming Wang,&nbsp;Kai Li,&nbsp;Jianhua Shi,&nbsp;Baohui Han,&nbsp;Lin Wu,&nbsp;Gongyan Chen,&nbsp;Jianxing He,&nbsp;Jie Wang,&nbsp;Haifeng Qin,&nbsp;Xiaoling Li","doi":"10.1002/cai2.43","DOIUrl":"https://doi.org/10.1002/cai2.43","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The prognosis of patients with small cell lung cancer (SCLC) and brain metastases (BM) was poor. This study aimed to explore the efficacy and safety of anlotinib as third-line or above treatment in SCLC with BM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a subgroup analysis of the ALTER1202 trial, which was a randomized, placebo-controlled trial aimed to evaluate the role of anlotinib as third-line treatment or above in patients with SCLC. This study included patients with BM at baseline. The efficacy and safety outcomes included progression-free survival (PFS), overall survival (OS), central nervous system (CNS), objective response rate (ORR), CNS disease control rate (DCR), time to CNS progression, and adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-one and nine patients with BM were included in the anlotinib and placebo groups, respectively. The median PFS and OS were 3.8 months (95% confidence interval [CI]: 1.8–6.1) and 6.1 months (95% CI: 4.1–8.0) in the anlotinib group. Anlotinib was associated with a significant improvement in PFS (hazard ratio [HR] = 0.15, 95% CI: 0.04–0.51, <i>p</i> = 0.0005) and OS (HR = 0.26, 95% CI: 0.09–0.73, <i>p</i> = 0.0061) than placebo. Anlotinib significantly prolonged the time to CNS progression (<i>p</i> &lt; 0.0001). The anlotinib group had a higher CNS DCR than placebo (95.2% vs. 22.2%, <i>p</i> = 0.0001). The most common grade 3 or higher AEs were increased lipase (19.0%), hypertension (14.3%), and hyponatremia (14.3%) in the anlotinib group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Anlotinib proved to have potential CNS activity and a manageable toxicity profile in patients with SCLC and BM, significantly delaying CNS progression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.43","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50151694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}